The downgrade from Buy to Hold by a major analyst firm like Jefferies, coupled with a drastic reduction in the price target, suggests a significant negative shift in the firm's outlook on Immuneering. This is likely to influence investor sentiment and could lead to a short-term decrease in the stock price, as market participants adjust their expectations based on this new analysis.